Drugs / recombinant human endostatin adenovirus
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07154108 | Sep 2025 → Aug 2027 expected | esophageal cancer, head and neck cancer | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02283489 | Oct 2014 → Oct 2016 | head and neck neoplasm | Renmiao Zhang | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human endostatin adenovirus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02283489 ↗ |
| Action | Inhibit | “Expression of this protein inhibits neovascular endothelial cells, neovascularization, and tumor growth and metastasis.” NCT02283489 ↗ |
| Route | Other | “Intratumor injection, once a week for 2 weeks” NCT02283489 ↗ |